Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Passage Bio Inc
Healthcare
P/NCAV
0.86x
Ticker
PASG
Exchange
NASDAQ
Country
United States
Close
1.23 $
Mkt Cap
67.3M $
EV
45.6M $
NCAV Burn Rate
49.2%
Current Ratio
7.22
Debt/Equity
0.0
EV/REV
N/Ax
EV/EBIT
-0.4x
EV/FCF
-0.6x
Dilution
6.8% p.A
Total Net Income
-594.2M $
Cheapness
92.0%
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional granulin gene, or GRN, encoding progranulin to the brain via intra cisterna magna administration. The lead indication for PBFT02 is frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-GRN. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington-s disease.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average